Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:N/A

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Contributing Authors: PD Miller N Pannacciulli JP Brown E Czerwinski BS Nedergaard MA Bolognese J Malouf HG Bone JY Reginster A Singer C Wang RB Wagman SR Cummings

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Explore some of our unlocked reports below!

Zoledronic acid increases BMD and prevents fracture risks in women with osteoporosis

Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women

Network meta-analysis of current drug options for the treatment of osteoporosis in men

Immediate effects on bone metabolism biomarkers noted with resistance training and walking

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

To view the full report, start your 30-day free trial today

Explore some of our unlocked reports below!

Continuing Medical Education Credits

Please be patient while we setup your OrthoEvidence account.

Please be patient
while we setup your
OrthoEvidence account.